Zimmer Biomet Keeps Focus on Innovation and New Products

In the midst of rebuilding, Zimmer Biomet has won an FDA nod for its Augmented Baseplate implant.

The last few years have become a time of change for Zimmer Biomet. In 2017, Bryan Hanson became the new president and CEO of Zimmer Biomet. Hanson’s mission was to get the company back on track after disappointing performance in some quarters.

Currently the Warsaw, IN-based company is making strides in this effort by getting regulatory approvals and clearances for its products. The latest offering from Zimmer Biomet to be cleared by FDA is the Augmented Baseplate. The company said it had recently completed the first surgical case using the technology with positive results.

“These implants allow the surgeons to maintain that good bone integrity, while addressing the deformity,” Orsa Britton, vice president and general manager of Zimmer Biomet’s global Extremities business, told MD+DI.

The baseplate offers an alternative to bone grafting and eccentric reaming for patients with glenoid defects undergoing shoulder reconstruction. The company said the baseplate boasts a simplified circular design at three augment heights (3mm, 5mm and 7mm buildup), allowing for augment placement in any orientation to accommodate various unique bone anatomies. Its circular design also allows bone ingrowth into the rim of the baseplate for optimal fixation.

 “Most of the patients that need the implant are going to need a reverse shoulder, and that could be for a variety of reasons,” Britton said. “Most of them are going to have a deformity on the glenoid, where they are going to need some additional augmentation that the implant can provide.”

Zimmer Biomet said the system aims to minimize the potential challenges of removing well-fixed humeral stems by allowing conversion to a reverse shoulder using any of the existing Comprehensive stems. Additionally, the Comprehensive Augmented Baseplate uses Mayo Clinic’s methodology for the optimization of shoulder arthroplasty components developed by Dr. Sperling at Mayo Clinic, Rochester, MN., to provide relevant sizing for a conservative approach to bone removal in order to preserve bone stock if a future revision procedure is necessary.

 “The implant is a small diameter base plate and it’s a half wedge, which means you can clock the wedge to the actual deformity,” Britton said. “This means you can dial it in to the specific issue the patient is presenting with.”

The company hasn’t been resting on its laurels when it comes to getting the story out about its products. In late March, Zimmer Biomet announced that the full seven-year follow-up data from a study evaluating the Company’s Mobi-C Cervical Disc for total disc replacement has been published in the peer-reviewed International Journal of Spine Surgery, the official scientific journal of the International Society for the Advancement of Spine Surgery (ISASS).

The data in the 599-patient study was favorable and showed at seven years, follow-up rates ranged from 73.5 percent to 84.4 percent (overall 80.2 percent). Overall success rates for two-level patients were 60.8 percent for cervical total disc replacement and 34.6 percent for anterior cervical discectomy and fusion.

500 characters remaining